-
Product Insights
NewLikelihood of Approval Analysis for Primary Progressive Multiple Sclerosis (PPMS)
Overview How likely is it that the drugs in Primary Progressive Multiple Sclerosis (PPMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Primary Progressive Multiple Sclerosis (PPMS) Overview Primary progressive multiple...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Hairy Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Hairy Cell Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Hairy Cell Leukemia Drug Details: Rituximab (MabThera, Rituxan,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BGB-3245 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BGB-3245 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BGB-3245 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: BGB-3245 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enitociclib in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enitociclib in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enitociclib in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Enitociclib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CGX-1321 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CGX-1321 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CGX-1321 in Colorectal Cancer Drug Details: CGX-1321 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Neuromyelitis Optica (Devic’s Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Neuromyelitis Optica (Devic's Syndrome) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Neuromyelitis Optica (Devic's Syndrome) Drug Details: Rituximab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Nodal Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Nodal Marginal Zone B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Nodal Marginal Zone B-Cell Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Extranodal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Splenic Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Splenic Marginal Zone B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Splenic Marginal Zone B-Cell Lymphoma Drug...